March 26, 2018 / 7:07 AM / 4 months ago

BRIEF-Biohaven Says Achieved Both Co-Primary Regulatory Endpoints In Two Pivotal Phase 3 Trials Of Rimegepant

March 26 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd:

* BIOHAVEN ANNOUNCES SUCCESSFUL ACHIEVEMENT OF BOTH CO-PRIMARY REGULATORY ENDPOINTS IN TWO PIVOTAL PHASE 3 TRIALS OF RIMEGEPANT AN ORAL CGRP RECEPTOR ANTAGONIST FOR THE ACUTE TREATMENT OF MIGRAINE

* RESULTS ARE STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL ACROSS MULTIPLE OUTCOME MEASURES

* EFFICACY AND SAFETY RESULTS WERE CONSISTENT ACROSS BOTH PHASE 3 TRIALS.

* ON SCHEDULE TO SUBMIT AN NDA FOR RIMEGEPANT IN 2019​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below